Developing therapeutic antibodies for Alzheimer's disease

项目总结/摘要 数以百万计的美国人患有阿尔茨海默氏症，目前还没有治疗方法可用于 预防或减缓疾病的进展。阿尔茨海默病患者未得到满足的医疗需求 导致美国每年有数千亿美元的有偿和无偿的医疗费用。 VersaPeutics是一家开发阿尔茨海默病新疗法的小企业。在本阶段I SBIR中， 我们将开展IND临床前研究，以研究药代动力学和药理学 主要药物产品的概况。在这些研究结束时，我们将达到几个重要的里程碑 这将支持我们治疗阿尔茨海默病的新疗法的进一步临床前开发。

PROJECT SUMMARY/ABSTRACT Millions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year. VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR project we will perform IND enabling preclinical studies to investigate pharmacokinetics and pharmacology profiles of leading drug product. At the conclusion of these studies, we will have met several important milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.